total radioactivity in organs in mice after intravenous and oral administration of [3H1-ET-18-OCH3 have been published (6).
The best-investigated ALP, ET-18-OCH3 (racemic-1-Ooctadecyl-2-O-methylglycero-3-phosphocholine) (B), has already entered phase II trials in human cancer therapy in the F.R.G. (5) . Concentrations in plasma and the distribution of Institut fiar PharmazeutischeChemie, WestfklischeWilhelmsUniversit#{228}t, Munster, F.RG. (wherethis work was done). 1 Current address and addressfor correspondence: College of Pharmacy(BoxJ-494), Department ofPharmaceutics, University of Florida, Gainesville, FL 32610.
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Received December 5, 1988;accepted February 1, 1989. total radioactivity in organs in mice after intravenous and oral administration of [3H1-ET-18-OCH3 have been published (6) .
Hitherto, no method has been available for quantifying non-radiolabeled ET-18-OCH3 in human plasma, because of the excess of endogenous phospholipids present in plasma and the difficulty of detecting ALP in low concentration. Therefore, a prerequisite to more information about the pharmacokinetics of ET-18-OCH3 in man is development of an assay for ALP in plasma.
Materials and Methods
Samples. Plasma samples were kept at -20 #{176}C until assayed.
Apparatus. We used a chromatogram-spectrophotometer 
Results and Discussion
The extraction step. Similarities in chemical structure and polarity between ET-18-OCH3 and endogenous glycerophospholipids make it very difficult to extract ET-18-OCH3 from human plasma specifically. Therefore ET-18-OCH3 has to be separated from natural lipids afterthe extraction. Separation and quantification in one step is more difficult because of excess of endogenous glycerophospholipids and the lack of chromophores that would allow sensitive and selective detection of ET-18-OCH3 in the presence of other phospholipids.
Lipids were extracted from plasma by use of a modification of the method of Foich et al. (7) . The analytical recovery was >97%.
Separation of different plasma lipids by thin-layer chromatography. The high amount of interfering phospholipids in the extract requires the use of one-dimension thin-layer chromatography for separation. Acid solvent systems are superior to basic mobile phases, because acid solvent systems are able to separate choline-, ethanolamine-, and serine-glycerophospholipids (8). Therefore no lysophosphatidylethanolamine or phosphatidylserine is present in the sphingomyelin fraction. This is important, because ET-18-OCH3 is located in the sphingomyelin fraction (Figure 1 ) and sphingomyelin can easily be separated from ET-18-OCH3 by the specific action of sphingomyelinase.
We have used a modification of an acid solvent system described by Skipski et al. (9) , which allows reproducible separation of plasma lipids. Although we tested many solvent systems, total separation between ET-18-OCH3 and plasma glycerophospholipids could not be achieved.
Analytical recove7y. A 24% loss of ET-18-OCH3 is observed during thin-layer chromatography separation and after extraction of the silica gel. The recovery aftercomplete isolation procedure was 73.5% (CV = 9.8%, n = 15). To quantify the loss of ET-18-OCH3 during extraction we used 
Quantification.
The standard curve for the densitometric determination of standards of ET-18-OCH3 at concentrations of 0 to 80 mg/L, corresponding toO to 400 ng of ET-18-OCH3 per spot, was linear ( Table 1 ). The mean correlation coefficient (r) was 0.997 (SD 0.002). The limit of detection was 4 mg/L (CV >30%), corresponding to 20 ng of ET-18-OCH3 per spot. The precision of the method was determined at six drug concentrations. A pooled plasma was split and supplemented to give concentrations from 0.1 to 5.0 mg/L. One sample of each concentration was assayed per day during one month. The interday CV and SD are given in Table 2 . The limit of detection was 0.1 mg/L (CV >30%).
Application.
For a preliminary determination of the pharmacokinetics of ET-18-OCH3, three patients were administered an oral dose of 150 mg of the drug every 4 h. Figure 3 illustrates the mean ET-18-OCH3 concentrations in plasma vs time. These results demonstrate that, after the oral intake of 150 mg, ET-18-OCH3 can be quantified in plasma with our I Th". N 
